https://www.soleburytrout.com/lifesciences Fri, 11 Dec 2020 22:04:38 +0000 Fri, 11 Dec 2020 22:04:38 +0000 60 en All rights reserved feeds@soundcloud.com (SoundCloud Feeds) Solebury Trout partners with private and public companies across sectors, helping management teams tackle complex investor relations challenges, capitalize on corporate communications opportunities, access the market and prepare for capital raising. More than 60 professionals with expertise in investor relations, equity research, portfolio management, private equity, investment banking and corporate communications work at Solebury Trout. The company was formed through the combination of Solebury Communications with the Trout Group, the premier investor relations and strategic advisory firm serving the biotechnology industry, providing corporate access and hosting dozens of well-attended conferences and thought leader events. Solebury Trout is affiliated with leading equity capital markets advisory firm Solebury Capital, which in 2017 advised on nearly 40 percent of the IPO proceeds in the U.S., and is owned by PNC, one of the largest diversified financial institutions in the country. Solebury Trout partners with private and public c… Solebury Trout Talks webinar@troutgroup.com Solebury Trout Talks no https://i1.sndcdn.com/avatars-FywJ5ko06kOPl6aV-jNzL2g-original.jpg https://www.soleburytrout.com/lifesciences tag:soundcloud,2010:tracks/932301226 Tue, 22 Dec 2020 17:27:27 +0000 https://soundcloud.com/trouttalks/juergen-horn-invetx-part-of-the-name-tag-series 00:26:36 Solebury Trout Talks no CEO and Founder of Invetx with the vision for Invetx to become the leading veterinary biotherapeutics company. 15+ years in various leadership roles in Marketing and R&D in the Animal Health industry and biotech. New product development for global markets with a focus to transfer and apply innovative technologies from human biotechnology to advance veterinary medicine. Previously Juergen was at Novartis Animal Health, Novartis Institute for Biomedical Research, Elanco/Lilly, Nexvet CEO and Founder of Invetx with the vision for Inv… CEO and Founder of Invetx with the vision for Invetx to become the leading veterinary biotherapeutics company. 15+ years in various leadership roles in Marketing and R&D in the Animal Health industry and biotech. New product development for global markets with a focus to transfer and apply innovative technologies from human biotechnology to advance veterinary medicine. Previously Juergen was at Novartis Animal Health, Novartis Institute for Biomedical Research, Elanco/Lilly, Nexvet tag:soundcloud,2010:tracks/945818395 Tue, 15 Dec 2020 14:33:11 +0000 https://soundcloud.com/trouttalks/jonathan-solomon-biomx-part-of-the-nametag-series 00:33:57 Solebury Trout Talks no Prior to his role in BiomX, Mr. Solomon was a co-founder, president, and CEO of ProClara (formerly NeuroPhage), which is pioneering an approach to treating neurodegenerative diseases. Under his leadership, the company raised more than $100 million and launched an ongoing clinical trial related to Alzheimer’s disease. Prior to that, he was selected to participate in the elite Israeli Defense Forces ‘Talpiot’ program, graduated as class valedictorian, and served for 10 years in a classified military unit. Mr. Solomon holds a B.Sc. magna cum laude in Physics and Mathematics from the Hebrew University, an M.Sc. summa cum laude in Electrical Engineering from Tel Aviv University, and an M.B.A. with honors from the Harvard Business School. Prior to his role in BiomX, Mr. Solomon was a co-… Prior to his role in BiomX, Mr. Solomon was a co-founder, president, and CEO of ProClara (formerly NeuroPhage), which is pioneering an approach to treating neurodegenerative diseases. Under his leadership, the company raised more than $100 million and launched an ongoing clinical trial related to Alzheimer’s disease. Prior to that, he was selected to participate in the elite Israeli Defense Forces ‘Talpiot’ program, graduated as class valedictorian, and served for 10 years in a classified military unit. Mr. Solomon holds a B.Sc. magna cum laude in Physics and Mathematics from the Hebrew University, an M.Sc. summa cum laude in Electrical Engineering from Tel Aviv University, and an M.B.A. with honors from the Harvard Business School. tag:soundcloud,2010:tracks/943210327 Mon, 14 Dec 2020 14:46:36 +0000 https://soundcloud.com/trouttalks/jonathan-drachman-neoleukin-therapeutics-part-of-the-nametag-series 00:43:47 Solebury Trout Talks no Jonathan is a seasoned clinician, researcher, and biopharmaceutical executive who joined Neoleukin at the company’s founding in 2018. For 14 years prior, he was at Seattle Genetics, where he most recently served as Chief Medical Officer and Executive Vice President of Research and Development. From 1998 to 2004, Dr. Drachman was a faculty member of the Division of Hematology at the University of Washington in Seattle, and a Senior Investigator in the Division of Research and Education at Puget Sound Blood Center. He currently serves on the board of directors for Calithera Biosciences and Harpoon Therapeutics. Dr. Drachman received a BA in Biochemistry from Harvard University and an MD from Harvard Medical School. He completed his residency in internal medicine and fellowship in medical oncology at the University of Washington. Jonathan is a seasoned clinician, researcher, and… Jonathan is a seasoned clinician, researcher, and biopharmaceutical executive who joined Neoleukin at the company’s founding in 2018. For 14 years prior, he was at Seattle Genetics, where he most recently served as Chief Medical Officer and Executive Vice President of Research and Development. From 1998 to 2004, Dr. Drachman was a faculty member of the Division of Hematology at the University of Washington in Seattle, and a Senior Investigator in the Division of Research and Education at Puget Sound Blood Center. He currently serves on the board of directors for Calithera Biosciences and Harpoon Therapeutics. Dr. Drachman received a BA in Biochemistry from Harvard University and an MD from Harvard Medical School. He completed his residency in internal medicine and fellowship in medical oncology at the University of Washington. tag:soundcloud,2010:tracks/945856423 Mon, 14 Dec 2020 13:46:19 +0000 https://soundcloud.com/trouttalks/dale-chappell-humanigen-part-of-the-nametag-series 00:24:48 Solebury Trout Talks no - Founder, Black Horse Capital Advisors - Decades of biotechnology investment experience - HHMI Fellow, National Cancer Institute, Rosenberg Lab - Multiple publications in T-cell therapy, GM-CSF and immunology pathways - Founder, Black Horse Capital Advisors - Decades… - Founder, Black Horse Capital Advisors - Decades of biotechnology investment experience - HHMI Fellow, National Cancer Institute, Rosenberg Lab - Multiple publications in T-cell therapy, GM-CSF and immunology pathways tag:soundcloud,2010:tracks/939570373 Thu, 03 Dec 2020 20:07:43 +0000 https://soundcloud.com/trouttalks/brandi-roberts-lineage-cell-therapeutics-part-of-the-nametag-series 00:24:26 Solebury Trout Talks no Ms. Roberts joined Lineage as Chief Financial Officer in January 2019. Prior to joining Lineage, Ms. Roberts served from August 2017 to January 2019 as Chief Financial Officer at REVA Medical, Inc. Ms. Roberts previously served as Chief Financial Officer at Mast Therapeutics, Inc. (MSTX), a publicly traded US-based biopharmaceutical company, from January 2013 to April 2017, having served as its Senior Vice President, Finance from March 2011 to January 2013. Previously, she held senior positions at Alphatec Spine, Artes Medical, Stratagene and Pfizer. Ms. Roberts brings more than 24 years of public accounting and finance experience, including 21 years at publicly traded pharmaceutical, medical technology, and life science companies to her position. Ms. Roberts is a certified public accountant with the State of California and received her B.S. degree in business administration from the University of Arizona and her M.B.A. from the University of San Diego. Ms. Roberts has served on the Board of Temple Therapeutics BV since November 2019. She also currently serves as Chair of the Southern California Chapter of the Association of Bioscience Financial Officers. Ms. Roberts joined Lineage as Chief Financial Off… Ms. Roberts joined Lineage as Chief Financial Officer in January 2019. Prior to joining Lineage, Ms. Roberts served from August 2017 to January 2019 as Chief Financial Officer at REVA Medical, Inc. Ms. Roberts previously served as Chief Financial Officer at Mast Therapeutics, Inc. (MSTX), a publicly traded US-based biopharmaceutical company, from January 2013 to April 2017, having served as its Senior Vice President, Finance from March 2011 to January 2013. Previously, she held senior positions at Alphatec Spine, Artes Medical, Stratagene and Pfizer. Ms. Roberts brings more than 24 years of public accounting and finance experience, including 21 years at publicly traded pharmaceutical, medical technology, and life science companies to her position. Ms. Roberts is a certified public accountant with the State of California and received her B.S. degree in business administration from the University of Arizona and her M.B.A. from the University of San Diego. Ms. Roberts has served on the Board of Temple Therapeutics BV since November 2019. She also currently serves as Chair of the Southern California Chapter of the Association of Bioscience Financial Officers. tag:soundcloud,2010:tracks/936083182 Mon, 30 Nov 2020 16:11:53 +0000 https://soundcloud.com/trouttalks/richard-godfrey-bergenbio-part-of-the-nametag-series-update 00:35:13 Solebury Trout Talks no Richard Godfrey joined BerGenBio as Chief Executive Officer in 2008. He has more than 25 years' industry experience leading many international drug development and commercialisation partnerships. Formerly he served as Chief Executive Officer of Aenova Inc., a specialist biopharmaceutical company. Prior to this he was the Managing Director of DCC Healthcare Ltd and previously he held positions of increasing responsibility at Catalant, Eli Lilly and Reckitt Benckiser in RnD and commercial roles. He qualified as a Pharmacist from Liverpool University and received his M.B.A. from Bath University. Richard Godfrey joined BerGenBio as Chief Executi… Richard Godfrey joined BerGenBio as Chief Executive Officer in 2008. He has more than 25 years' industry experience leading many international drug development and commercialisation partnerships. Formerly he served as Chief Executive Officer of Aenova Inc., a specialist biopharmaceutical company. Prior to this he was the Managing Director of DCC Healthcare Ltd and previously he held positions of increasing responsibility at Catalant, Eli Lilly and Reckitt Benckiser in RnD and commercial roles. He qualified as a Pharmacist from Liverpool University and received his M.B.A. from Bath University. tag:soundcloud,2010:tracks/934743100 Tue, 24 Nov 2020 19:05:23 +0000 https://soundcloud.com/trouttalks/pawel-przewiezlikowski-ryvu-part-of-the-name-tag-series 00:21:45 Solebury Trout Talks no Mr. Przewiezlikowski is the Chief Executive Officer and founder of Ryvu Therapeutics, responsible for strategic management, business and corporate development of the company. He is also the President of Supervisory Board at Ardigen and Member of the Supervisory Board at Selvita. Before founding multiple companies in the biotechnology sector (Ryvu, Ardigen, NodThera), Mr. Przewiezlikowski was a member of the executive team at technology company Comarch, responsible for divisions involved in multiple industries including the pharmaceutical industry. He was also the co-founder, the first CEO and then the Vice President of the Supervisory Board of Interia.pl, the third largest Internet portal in Poland. Mr. Przewiezlikowski is a member of the Economic Council of the Malopolska (Krakow) region. He was awarded Knight’s Cross of the Order of Polonia Restituta for his contributions to the development of Poland’s business environment, as well as, EY Entrepreneur of the Year 2015 award in the New Technologies/Innovation category in Poland. Mr. Przewiezlikowski holds an MBA from the joint program of the Teesside University (United Kingdom) and Krakow School of Economics (Poland) as well as master degree in computer science from AGH Technical University in Krakow. He also studied IT at the Technical University in Berlin. Mr. Przewiezlikowski is the Chief Executive Offic… Mr. Przewiezlikowski is the Chief Executive Officer and founder of Ryvu Therapeutics, responsible for strategic management, business and corporate development of the company. He is also the President of Supervisory Board at Ardigen and Member of the Supervisory Board at Selvita. Before founding multiple companies in the biotechnology sector (Ryvu, Ardigen, NodThera), Mr. Przewiezlikowski was a member of the executive team at technology company Comarch, responsible for divisions involved in multiple industries including the pharmaceutical industry. He was also the co-founder, the first CEO and then the Vice President of the Supervisory Board of Interia.pl, the third largest Internet portal in Poland. Mr. Przewiezlikowski is a member of the Economic Council of the Malopolska (Krakow) region. He was awarded Knight’s Cross of the Order of Polonia Restituta for his contributions to the development of Poland’s business environment, as well as, EY Entrepreneur of the Year 2015 award in the New Technologies/Innovation category in Poland. Mr. Przewiezlikowski holds an MBA from the joint program of the Teesside University (United Kingdom) and Krakow School of Economics (Poland) as well as master degree in computer science from AGH Technical University in Krakow. He also studied IT at the Technical University in Berlin. tag:soundcloud,2010:tracks/933042490 Fri, 20 Nov 2020 21:50:42 +0000 https://soundcloud.com/trouttalks/david-parkinson-essa-pharma-part-of-the-name-tag-series 00:32:02 Solebury Trout Talks no Dr. Parkinson has served as President and Chief Executive Officer of ESSA Pharma Inc. since January 2016, and as a Director of the company since June 2015. Prior to joining ESSA he had been a Venture Partner at New Enterprise Associates, Inc. From 2007 until 2012, Dr. Parkinson served as President and CEO of Nodality, Inc., a biotechnology company focused on the biological characterization of signaling pathways in patients with malignancy. Until October 2007 he was SVP, Oncology Research and Development at Biogen Idec, where he oversaw all oncology discovery research efforts and the development of the oncology pipeline. Previously he had served as VP, Oncology Development, at Amgen and VP, Global Clinical Oncology Development, at Novartis. In those roles he oversaw the successful clinical development of a series of cancer therapeutics, including Gleevec, Zometa, Femara, and Vectibix. Dr. Parkinson worked at the National Cancer Institute from 1990 to 1997, serving as Chief of the Investigational Drug Branch and then as Acting Associate Director of the Cancer Therapy Evaluation Program (CTEP). He is a past Chairman of the Food & Drug Administration (FDA) Biologics Advisory Committee, a past member of the FDA Science Board, and is a recipient of the FDA’s Cody Medal. He is a past editor of the Journal of Immunotherapy and past president of the Society of Biological Therapy. He has served on the National Cancer Policy Forum of the Institute of Medicine and is a past co-chair of the Cancer Steering Committee of the NIH Foundation Biomarkers Consortium. A past Board Director of the Ontario Institute for Cancer Research, he currently serves as a Board Director for the Multiple Myeloma Research Foundation. He served as Chairperson of the American Association of Cancer Research (AACR) Finance and Audit Committee for 15 years and is a previous elected Board Director of AACR. Dr. Parkinson was a Director of Facet Biotech, Inc., until the acquisition by Abbott Pharmaceuticals, and was a Director of Ambit Biosciences until the acquisition by Daiichi Sankyo. He was also previously a Director at Threshold Pharmaceuticals and Cerulean Pharmaceuticals. He currently serves as Director on the Boards of CTI Biopharma, Inc (CTIC), 3SBio Inc (1530.HK) and is a Co-Founder and Director of Refuge Biotech, Inc. He has held academic positions both at Tufts and at the University of Texas MD Anderson Cancer Center, and has authored over 100 peer-reviewed publications. Dr. Parkinson has served as President and Chief E… Dr. Parkinson has served as President and Chief Executive Officer of ESSA Pharma Inc. since January 2016, and as a Director of the company since June 2015. Prior to joining ESSA he had been a Venture Partner at New Enterprise Associates, Inc. From 2007 until 2012, Dr. Parkinson served as President and CEO of Nodality, Inc., a biotechnology company focused on the biological characterization of signaling pathways in patients with malignancy. Until October 2007 he was SVP, Oncology Research and Development at Biogen Idec, where he oversaw all oncology discovery research efforts and the development of the oncology pipeline. Previously he had served as VP, Oncology Development, at Amgen and VP, Global Clinical Oncology Development, at Novartis. In those roles he oversaw the successful clinical development of a series of cancer therapeutics, including Gleevec, Zometa, Femara, and Vectibix. Dr. Parkinson worked at the National Cancer Institute from 1990 to 1997, serving as Chief of the Investigational Drug Branch and then as Acting Associate Director of the Cancer Therapy Evaluation Program (CTEP). He is a past Chairman of the Food & Drug Administration (FDA) Biologics Advisory Committee, a past member of the FDA Science Board, and is a recipient of the FDA’s Cody Medal. He is a past editor of the Journal of Immunotherapy and past president of the Society of Biological Therapy. He has served on the National Cancer Policy Forum of the Institute of Medicine and is a past co-chair of the Cancer Steering Committee of the NIH Foundation Biomarkers Consortium. A past Board Director of the Ontario Institute for Cancer Research, he currently serves as a Board Director for the Multiple Myeloma Research Foundation. He served as Chairperson of the American Association of Cancer Research (AACR) Finance and Audit Committee for 15 years and is a previous elected Board Director of AACR. Dr. Parkinson was a Director of Facet Biotech, Inc., until the acquisition by Abbott Pharmaceuticals, and was a Director of Ambit Biosciences until the acquisition by Daiichi Sankyo. He was also previously a Director at Threshold Pharmaceuticals and Cerulean Pharmaceuticals. He currently serves as Director on the Boards of CTI Biopharma, Inc (CTIC), 3SBio Inc (1530.HK) and is a Co-Founder and Director of Refuge Biotech, Inc. He has held academic positions both at Tufts and at the University of Texas MD Anderson Cancer Center, and has authored over 100 peer-reviewed publications. tag:soundcloud,2010:tracks/930892822 Thu, 19 Nov 2020 14:09:13 +0000 https://soundcloud.com/trouttalks/lucy-lu-kintor-pharmaceutical-part-of-the-name-tag-series 00:22:16 Solebury Trout Talks no Over 13 years of experience in investment banking business Former Director and Managing Director of GF Capital (Hong Kong) Former executive director of UBS Hong Kong in Asia healthcare group Obtained the sponsor license of Hong Kong listing in 2014 Over 13 years of experience in investment banking… Over 13 years of experience in investment banking business Former Director and Managing Director of GF Capital (Hong Kong) Former executive director of UBS Hong Kong in Asia healthcare group Obtained the sponsor license of Hong Kong listing in 2014 tag:soundcloud,2010:tracks/871979239 Mon, 14 Sep 2020 18:16:11 +0000 https://soundcloud.com/trouttalks/srinivas-rao-atai-life-sciences-part-of-the-name-tag-series 00:26:22 Solebury Trout Talks no Srinivas Rao is the Chief Scientific Officer at ATAI Life Sciences AG. Dr. has over 19 years of professional experience in the pharmaceutical and biotechnology industries. Prior to ATAI, Dr. Rao has held the titles of Chief Scientific, Medical, or Executive Officer at companies ranging from venture backed startups to vertically-integrated, publicly traded pharmaceutical companies. Dr. Rao completed an internship in Internal Medicine at Yale-New Haven Hospital. He received his Ph.D. in neurobiology from Yale Graduate School and his M.D. from Yale School of Medicine. He holds both a Bachelor of Science and Master of Science degree in Electrical Engineering from Yale College and Yale Graduate School, respectively. Srinivas Rao is the Chief Scientific Officer at A… Srinivas Rao is the Chief Scientific Officer at ATAI Life Sciences AG. Dr. has over 19 years of professional experience in the pharmaceutical and biotechnology industries. Prior to ATAI, Dr. Rao has held the titles of Chief Scientific, Medical, or Executive Officer at companies ranging from venture backed startups to vertically-integrated, publicly traded pharmaceutical companies. Dr. Rao completed an internship in Internal Medicine at Yale-New Haven Hospital. He received his Ph.D. in neurobiology from Yale Graduate School and his M.D. from Yale School of Medicine. He holds both a Bachelor of Science and Master of Science degree in Electrical Engineering from Yale College and Yale Graduate School, respectively. tag:soundcloud,2010:tracks/873577960 Fri, 28 Aug 2020 16:04:35 +0000 https://soundcloud.com/trouttalks/david-main-notch-therapeutics-part-of-the-name-tag-series 00:22:25 Solebury Trout Talks no David Main is President and Chief Executive Officer of Notch Therapeutics. Previously, as Chairman and CEO of Aquinox Pharmaceuticals, a company he founded in 2004, Mr. Main oversaw the advancement of the company’s lead product from target validation through Phase 3 clinical trials. He also led the transition of Aquinox from a private company to a NASDAQ-listed public company with approximately $300 million raised in equity capital and then completed the successful merger of Aquinox with Neoleukin Therapeutics. Prior to his leadership of Aquinox, David served as President and CEO of INEX Pharmaceuticals and as a Vice President of QLT. He formerly served as the Chair of LifeSciences BC (formerly BC Biotech), BIOTECanada, and Accel-Rx as well as a Director of BIO.org. David began his career as a licensed pharmacist at the Royal Columbian Hospital in New Westminster, B.C. He holds a B.Sc. (Pharmacy) and an MBA from the University of British Columbia (UBC). David Main is President and Chief Executive Offic… David Main is President and Chief Executive Officer of Notch Therapeutics. Previously, as Chairman and CEO of Aquinox Pharmaceuticals, a company he founded in 2004, Mr. Main oversaw the advancement of the company’s lead product from target validation through Phase 3 clinical trials. He also led the transition of Aquinox from a private company to a NASDAQ-listed public company with approximately $300 million raised in equity capital and then completed the successful merger of Aquinox with Neoleukin Therapeutics. Prior to his leadership of Aquinox, David served as President and CEO of INEX Pharmaceuticals and as a Vice President of QLT. He formerly served as the Chair of LifeSciences BC (formerly BC Biotech), BIOTECanada, and Accel-Rx as well as a Director of BIO.org. David began his career as a licensed pharmacist at the Royal Columbian Hospital in New Westminster, B.C. He holds a B.Sc. (Pharmacy) and an MBA from the University of British Columbia (UBC). tag:soundcloud,2010:tracks/874672852 Wed, 19 Aug 2020 15:35:14 +0000 https://soundcloud.com/trouttalks/brian-culley-lineage-cell-therapeutics-part-of-the-timestamp-series 00:32:00 Solebury Trout Talks no Mr. Culley joined Lineage as CEO in September 2018. Prior to joining Lineage, Mr. Culley served from August 2017 to September 17, 2018 as Interim Chief Executive Officer at Artemis Therapeutics, Inc., a, where he was responsible for the management of the company. Mr. Culley previously served as Chief Executive Officer of Mast Therapeutics, Inc. (“Mast”), from February 2010, and was also a member of its Board of Directors from December 2011, until Mast’s merger with Savara, Inc. in April 2017. Mr. Culley served from January 2007 to February 2010 as Mast’s Chief Business Officer and Senior Vice President, from February 2006 to January 2007 as Mast’s Senior Vice President, Business Development, and from December 2004 to February 2006 as Mast’s Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. Mr. Culley has more than 25 years of business and scientific experience in the life sciences industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University. Mr. Culley joined Lineage as CEO in September 201… Mr. Culley joined Lineage as CEO in September 2018. Prior to joining Lineage, Mr. Culley served from August 2017 to September 17, 2018 as Interim Chief Executive Officer at Artemis Therapeutics, Inc., a, where he was responsible for the management of the company. Mr. Culley previously served as Chief Executive Officer of Mast Therapeutics, Inc. (“Mast”), from February 2010, and was also a member of its Board of Directors from December 2011, until Mast’s merger with Savara, Inc. in April 2017. Mr. Culley served from January 2007 to February 2010 as Mast’s Chief Business Officer and Senior Vice President, from February 2006 to January 2007 as Mast’s Senior Vice President, Business Development, and from December 2004 to February 2006 as Mast’s Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. Mr. Culley has more than 25 years of business and scientific experience in the life sciences industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University. tag:soundcloud,2010:tracks/875239420 Tue, 18 Aug 2020 19:05:24 +0000 https://soundcloud.com/trouttalks/rob-de-ree-northsea-part-of-the-nametag-series 00:30:57 Solebury Trout Talks no Prior to joining NorthSea Therapeutics B.V., Rob de Ree served as the CEO of the start-up companies Dezima Pharma, which was acquired by Amgen in 2015 and as the CEO of BMEYE which was acquired by Edwards lifesciences in 2012. Before that Rob de Ree served as the head of the licensing business of Crucell and in various national and international sales and marketing roles at Medtronic. Rob de Ree started his career in pharma in 1991 in sales and marketing at the cardiovascular division of Byk Gulden in the Netherlands. In addition Rob de Ree is currently a board member at Ventinova (chair) and Mellon medical and operating partner at Biogeneration Ventures. Rob de Ree holds an MSc in pharmacy from the University of Groningen. Prior to joining NorthSea Therapeutics B.V., Rob … Prior to joining NorthSea Therapeutics B.V., Rob de Ree served as the CEO of the start-up companies Dezima Pharma, which was acquired by Amgen in 2015 and as the CEO of BMEYE which was acquired by Edwards lifesciences in 2012. Before that Rob de Ree served as the head of the licensing business of Crucell and in various national and international sales and marketing roles at Medtronic. Rob de Ree started his career in pharma in 1991 in sales and marketing at the cardiovascular division of Byk Gulden in the Netherlands. In addition Rob de Ree is currently a board member at Ventinova (chair) and Mellon medical and operating partner at Biogeneration Ventures. Rob de Ree holds an MSc in pharmacy from the University of Groningen. tag:soundcloud,2010:tracks/874188247 Wed, 12 Aug 2020 20:24:55 +0000 https://soundcloud.com/trouttalks/theresa-heah-asclepix-part-of-the-name-tag-series 00:25:50 Solebury Trout Talks no Prior to joining AsclepiX Therapeutics, Dr. Heah served as Chief Medical Officer at Applied Genetic Technologies Corporation (AGTC), where she worked on developing ophthalmic gene therapies. Before her tenure at AGTC, Dr. Heah was Vice President, Global Head of Clinical Research, Medical and Professional Affairs at Aerie Pharmaceuticals, where she played a key role in driving growth and success of the organization globally. In this position, Dr. Heah was responsible for global strategy and development of ophthalmology programs, leading an experienced team executing clinical research, clinical operations, medical affairs, and professional affairs. During her tenure, she successfully expanded her global team size from 10 to 52 professionals and took a leading role in Aerie’s pharmaceutical development program for milestone product candidates, including Rhopressa® and Rocklatan®.Prior to her tenure at Aerie, Dr. Heah served with increasing responsibility, initially as the Director, Senior Global Medical Affairs Physician lead in the worldwide launch of EYLEA® followed by the role of Global Strategic Marketing Director at Bayer Healthcare Pharmaceuticals, where she served as the brand plan lead for EYLEA, an anti-VEGF compound indicated for the management of 5 retinal diseases. As part of her work on EYLEA, Dr. Heah oversaw the development of brand strategy, positioning, market research, advisory boards, key message development, pricing & reimbursement, and promotional campaigns. While at Bayer, her product portfolio’s value exceeded €1B annually. Dr. Heah has clinical experience as an ophthalmologist in the U.K. Dr. Heah earned her Doctorate of Medicine from Guy’s Kings and St. Thomas’ School of Medicine, King’s College, University of London, and her Executive Master’s in Business Administration from the European School of Management & Technology (ESMT), Berlin. Prior to joining AsclepiX Therapeutics, Dr. Heah … Prior to joining AsclepiX Therapeutics, Dr. Heah served as Chief Medical Officer at Applied Genetic Technologies Corporation (AGTC), where she worked on developing ophthalmic gene therapies. Before her tenure at AGTC, Dr. Heah was Vice President, Global Head of Clinical Research, Medical and Professional Affairs at Aerie Pharmaceuticals, where she played a key role in driving growth and success of the organization globally. In this position, Dr. Heah was responsible for global strategy and development of ophthalmology programs, leading an experienced team executing clinical research, clinical operations, medical affairs, and professional affairs. During her tenure, she successfully expanded her global team size from 10 to 52 professionals and took a leading role in Aerie’s pharmaceutical development program for milestone product candidates, including Rhopressa® and Rocklatan®.Prior to her tenure at Aerie, Dr. Heah served with increasing responsibility, initially as the Director, Senior Global Medical Affairs Physician lead in the worldwide launch of EYLEA® followed by the role of Global Strategic Marketing Director at Bayer Healthcare Pharmaceuticals, where she served as the brand plan lead for EYLEA, an anti-VEGF compound indicated for the management of 5 retinal diseases. As part of her work on EYLEA, Dr. Heah oversaw the development of brand strategy, positioning, market research, advisory boards, key message development, pricing & reimbursement, and promotional campaigns. While at Bayer, her product portfolio’s value exceeded €1B annually. Dr. Heah has clinical experience as an ophthalmologist in the U.K. Dr. Heah earned her Doctorate of Medicine from Guy’s Kings and St. Thomas’ School of Medicine, King’s College, University of London, and her Executive Master’s in Business Administration from the European School of Management & Technology (ESMT), Berlin. tag:soundcloud,2010:tracks/870835873 Thu, 06 Aug 2020 14:48:41 +0000 https://soundcloud.com/trouttalks/niquette-hunt-candesant-part-of-the-nametag-series 00:23:52 Solebury Trout Talks no Niqui has over 25 years experience in developing, launching and commercially scaling 20+ products in both large corporations (P&G, Warner Lambert) and early stage companies across multiple verticals in the consumer medicine market. Every business she managed has increased sales, profits and/or market share. Prior to Candesant, she led the commercial strategy at Revance Therapeutics and helped raise over $250M in the company’s 2014 IPO and follow-on financing. Niqui has over 25 years experience in developing,… Niqui has over 25 years experience in developing, launching and commercially scaling 20+ products in both large corporations (P&G, Warner Lambert) and early stage companies across multiple verticals in the consumer medicine market. Every business she managed has increased sales, profits and/or market share. Prior to Candesant, she led the commercial strategy at Revance Therapeutics and helped raise over $250M in the company’s 2014 IPO and follow-on financing. tag:soundcloud,2010:tracks/869610889 Tue, 04 Aug 2020 13:10:57 +0000 https://soundcloud.com/trouttalks/alex-zapesochny-clerio-vision-part-of-the-nametag-series 00:33:45 Solebury Trout Talks no Alex is an experienced technology executive and attorney who previously served as Executive Vice President of Cardiac Safety at ERT. A co-founder of iCardiac Technologies, Alex served as its President and CEO until ERT acquired the company in late 2017. He founded iCardiac with Mike Totterman and Sasha Latypova. Prior to joining iCardiac, Alex was General Counsel and Director of Business Development for Lenel Systems International, a developer and global supplier of high-end software, products and services for the security industry. Alex was part of a small executive management team that guided the company to extraordinary growth. The company expanded to serving over 10,000 organizations throughout 75 countries, including security-conscious entities such as Microsoft, Cisco, all three New York City-area airports, the Department of Homeland Security and over 60 percent of all Fortune 100 companies. The company’s financial growth earned it 39th place on Inc. magazine’s ranking of the nation’s fastest-growing privately-held companies, and Lenel was acquired for $440 million by United Technologies Corporation (NYSE: UTX) in March 2005.Alex remained with UTC after the acquisition and continued in his legal and business development roles within the Lenel Systems subsidiary. Alex, who is known for interest in entrepreneurial activity, provides legal and business counsel to early-stage companies. He has been a trial attorney during his tenure as a New York City prosecutor, a policy division staff member in the Washington headquarters of a presidential campaign, and Co-Founder and Executive Director of an award-winning non-profit that expands the national registry of potential bone marrow and blood stem cell donors. Alex received his undergraduate degree from Cornell University and graduate degrees from American University, University of Oxford and the University of Cambridge. Alex is an experienced technology executive and a… Alex is an experienced technology executive and attorney who previously served as Executive Vice President of Cardiac Safety at ERT. A co-founder of iCardiac Technologies, Alex served as its President and CEO until ERT acquired the company in late 2017. He founded iCardiac with Mike Totterman and Sasha Latypova. Prior to joining iCardiac, Alex was General Counsel and Director of Business Development for Lenel Systems International, a developer and global supplier of high-end software, products and services for the security industry. Alex was part of a small executive management team that guided the company to extraordinary growth. The company expanded to serving over 10,000 organizations throughout 75 countries, including security-conscious entities such as Microsoft, Cisco, all three New York City-area airports, the Department of Homeland Security and over 60 percent of all Fortune 100 companies. The company’s financial growth earned it 39th place on Inc. magazine’s ranking of the nation’s fastest-growing privately-held companies, and Lenel was acquired for $440 million by United Technologies Corporation (NYSE: UTX) in March 2005.Alex remained with UTC after the acquisition and continued in his legal and business development roles within the Lenel Systems subsidiary. Alex, who is known for interest in entrepreneurial activity, provides legal and business counsel to early-stage companies. He has been a trial attorney during his tenure as a New York City prosecutor, a policy division staff member in the Washington headquarters of a presidential campaign, and Co-Founder and Executive Director of an award-winning non-profit that expands the national registry of potential bone marrow and blood stem cell donors. Alex received his undergraduate degree from Cornell University and graduate degrees from American University, University of Oxford and the University of Cambridge. tag:soundcloud,2010:tracks/869589070 Tue, 04 Aug 2020 12:59:56 +0000 https://soundcloud.com/trouttalks/vishal-doshi-aum-biosciences-part-of-the-nametag-series 00:35:18 Solebury Trout Talks no Extensive experience in structuring and managing risk sharing deals in various roles worth over $1 billion USD. Extensive experience in clinical research across the pharmaceutical and CRO industry, spanning US, Europe and Asia. Key Opinion Leader to Korean Health Industry Development Institute Previously held senior business development and management roles at IQVIA, EPS International and ICON. Master’s Degree in Pharmaceutical Sciences from Kingston University with research focus in Aromatase inhibitors in Breast cancer. Bachelor of Pharmacy from University of Mumbai. Extensive experience in structuring and managing … Extensive experience in structuring and managing risk sharing deals in various roles worth over $1 billion USD. Extensive experience in clinical research across the pharmaceutical and CRO industry, spanning US, Europe and Asia. Key Opinion Leader to Korean Health Industry Development Institute Previously held senior business development and management roles at IQVIA, EPS International and ICON. Master’s Degree in Pharmaceutical Sciences from Kingston University with research focus in Aromatase inhibitors in Breast cancer. Bachelor of Pharmacy from University of Mumbai. tag:soundcloud,2010:tracks/867993676 Mon, 03 Aug 2020 19:18:14 +0000 https://soundcloud.com/trouttalks/robert-geho-diasome-part-of-the-nametag-series 00:45:36 Solebury Trout Talks no Mr. Geho has twenty-five years of experience in the field of diabetes drug development and is a recognized leader in the industry’s effort to develop novel insulin therapies for people with Type 1 and Type 2 diabetes. As a patient-entrepreneur, he has been a dedicated team member and leader in the execution of more than twenty different human clinical studies designed to test various forms of both injected and oral insulins for diabetes, including the first ever Phase 2b study of oral liver targeted insulin and the first ever Phase 2b study of injected liver targeted mealtime insulin. In his role at Diasome, he is responsible for aligning technology, clinical, and business teams in Diasome’s work to achieve the first approved liver targeted insulin therapy. Mr. Geho received his undergraduate degree from both The Cleveland Institute of Music and Case Western Reserve University and his MBA from The Weatherhead School of Management at CWRU. Mr. Geho has twenty-five years of experience in t… Mr. Geho has twenty-five years of experience in the field of diabetes drug development and is a recognized leader in the industry’s effort to develop novel insulin therapies for people with Type 1 and Type 2 diabetes. As a patient-entrepreneur, he has been a dedicated team member and leader in the execution of more than twenty different human clinical studies designed to test various forms of both injected and oral insulins for diabetes, including the first ever Phase 2b study of oral liver targeted insulin and the first ever Phase 2b study of injected liver targeted mealtime insulin. In his role at Diasome, he is responsible for aligning technology, clinical, and business teams in Diasome’s work to achieve the first approved liver targeted insulin therapy. Mr. Geho received his undergraduate degree from both The Cleveland Institute of Music and Case Western Reserve University and his MBA from The Weatherhead School of Management at CWRU. tag:soundcloud,2010:tracks/868095769 Fri, 31 Jul 2020 22:49:41 +0000 https://soundcloud.com/trouttalks/zach-hornby-boundless-bio-part-of-the-nametag-series 00:21:41 Solebury Trout Talks no Zachary (“Zach”) Hornby has served in executive and director roles for multiple private and public biotechnology companies. Prior to joining Boundless Bio, Zach was Chief Executive Officer, President and a Director at Optera Therapeutics Corp, a company that was developing multiple clinical-stage cellular therapies that had been innovated at MD Anderson Cancer Center. Before that, he was Chief Operating Officer at Ignyta, where he oversaw development of the company’s portfolio of four clinical stage therapeutics and was the team leader for the company’s lead program, entrectinib, which was the first drug in pharmaceutical history to garner the coveted BTD (FDA), PRIME (EMA) and Sakigake (PMDA) designations. In that role, he also led the business development process that resulted in Ignyta’s acquisition by Roche for $2 billion; after the Roche acquisition, Zach served as the Ignyta site head where he was responsible for overseeing the integration into Roche. Before assuming the COO role, Zach was Ignyta’s Chief Financial Officer, helping the company go public and raise $120 million in capital. Prior to joining Ignyta, Zach served in roles of increasing responsibility across business development, marketing, new product planning, finance, and regulatory affairs at Fate Therapeutics, Halozyme Therapeutics, Neurocrine Biosciences and Transkaryotic Therapeutics (“TKT;” now the Human Genetic Therapies division within Takeda/Shire) and was a life sciences consultant at L.E.K. Consulting. Zach holds B.S. and M.S. degrees in biology, with a concentration in neuroscience, from Stanford University and an MBA from Harvard Business School. Zachary (“Zach”) Hornby has served in executive a… Zachary (“Zach”) Hornby has served in executive and director roles for multiple private and public biotechnology companies. Prior to joining Boundless Bio, Zach was Chief Executive Officer, President and a Director at Optera Therapeutics Corp, a company that was developing multiple clinical-stage cellular therapies that had been innovated at MD Anderson Cancer Center. Before that, he was Chief Operating Officer at Ignyta, where he oversaw development of the company’s portfolio of four clinical stage therapeutics and was the team leader for the company’s lead program, entrectinib, which was the first drug in pharmaceutical history to garner the coveted BTD (FDA), PRIME (EMA) and Sakigake (PMDA) designations. In that role, he also led the business development process that resulted in Ignyta’s acquisition by Roche for $2 billion; after the Roche acquisition, Zach served as the Ignyta site head where he was responsible for overseeing the integration into Roche. Before assuming the COO role, Zach was Ignyta’s Chief Financial Officer, helping the company go public and raise $120 million in capital. Prior to joining Ignyta, Zach served in roles of increasing responsibility across business development, marketing, new product planning, finance, and regulatory affairs at Fate Therapeutics, Halozyme Therapeutics, Neurocrine Biosciences and Transkaryotic Therapeutics (“TKT;” now the Human Genetic Therapies division within Takeda/Shire) and was a life sciences consultant at L.E.K. Consulting. Zach holds B.S. and M.S. degrees in biology, with a concentration in neuroscience, from Stanford University and an MBA from Harvard Business School. tag:soundcloud,2010:tracks/867424306 Thu, 30 Jul 2020 23:45:59 +0000 https://soundcloud.com/trouttalks/bill-enright-vaccitech-part-of-the-nametag-series 00:34:55 Solebury Trout Talks no William “Bill” Enright is a seasoned biotech executive with more than thirty years of experience in building and financing both privately held and publicly held companies. Bill spent more than ten years at Altimmune (NASDAQ: ALT) as a Director, President & CEO, moving multiple programs into clinical testing, completing several acquisitions and eventually taking the company public. Prior to joining Altimmune, Bill spent six years with GenVec, Inc. (acquired by Intrexon) with increasing responsibilities, which included a role as Head of Business Development. Bill has raised more than $300 million through private, public and non-dilutive financings. Bill brings a breadth of experiences in a variety of positions within the life science/biotech industry, including time as a consultant, a bench scientist and 12 years with Life Technologies, Inc. (acquired by Thermo-Fisher), working in various senior level licensing, business management, manufacturing and research roles. Bill received a Master of Arts in Molecular Biology from SUNY at Buffalo and a Master of Science in Business Management from Johns Hopkins University. William “Bill” Enright is a seasoned biotech exec… William “Bill” Enright is a seasoned biotech executive with more than thirty years of experience in building and financing both privately held and publicly held companies. Bill spent more than ten years at Altimmune (NASDAQ: ALT) as a Director, President & CEO, moving multiple programs into clinical testing, completing several acquisitions and eventually taking the company public. Prior to joining Altimmune, Bill spent six years with GenVec, Inc. (acquired by Intrexon) with increasing responsibilities, which included a role as Head of Business Development. Bill has raised more than $300 million through private, public and non-dilutive financings. Bill brings a breadth of experiences in a variety of positions within the life science/biotech industry, including time as a consultant, a bench scientist and 12 years with Life Technologies, Inc. (acquired by Thermo-Fisher), working in various senior level licensing, business management, manufacturing and research roles. Bill received a Master of Arts in Molecular Biology from SUNY at Buffalo and a Master of Science in Business Management from Johns Hopkins University. tag:soundcloud,2010:tracks/867287599 Thu, 30 Jul 2020 18:38:32 +0000 https://soundcloud.com/trouttalks/richard-andrews-azitra-part-of-the-nametag-series 00:38:10 Solebury Trout Talks no Mr. Andrews has spent most of his career as a C level executive leading operations, finance, and commercial and clinical development for biotechnology firms focused on new products that address inflammatory disease. Mr. Andrews has been instrumental in translating research and academic discoveries into product development and advanced clinical programs, building alliances and partnerships and organizing operational teams. Financing processes led by Mr. Andrews have secured over $130M in equity funding for new ventures. His work has been primarily focused on skin disease, pneumonia, infant hypoxic ischemia and kidney failure. Early in his career, Mr. Andrews led the commercialization of several natural cell systems to prevent disease on fruits and vegetables and launched several DNA diagnostic tests for periodontal disease. Mr. Andrews received graduate degrees in physical biochemistry (MS), and technology management (SM) from Purdue University, and the Massachusetts Institute of Technology, respectively. He also has an undergraduate degree in Chemistry (BS) from Hobart College. Mr. Andrews has spent most of his career as a C l… Mr. Andrews has spent most of his career as a C level executive leading operations, finance, and commercial and clinical development for biotechnology firms focused on new products that address inflammatory disease. Mr. Andrews has been instrumental in translating research and academic discoveries into product development and advanced clinical programs, building alliances and partnerships and organizing operational teams. Financing processes led by Mr. Andrews have secured over $130M in equity funding for new ventures. His work has been primarily focused on skin disease, pneumonia, infant hypoxic ischemia and kidney failure. Early in his career, Mr. Andrews led the commercialization of several natural cell systems to prevent disease on fruits and vegetables and launched several DNA diagnostic tests for periodontal disease. Mr. Andrews received graduate degrees in physical biochemistry (MS), and technology management (SM) from Purdue University, and the Massachusetts Institute of Technology, respectively. He also has an undergraduate degree in Chemistry (BS) from Hobart College. tag:soundcloud,2010:tracks/825944329 Thu, 28 May 2020 16:34:30 +0000 https://soundcloud.com/trouttalks/takashi-kei-kishimoto-selecta-bio-part-of-the-nametag-series 00:35:34 Solebury Trout Talks no Prior to joining Selecta Biosciences in 2011, Dr. Kishimoto was Vice President of Discovery Research at Momenta Pharmaceuticals, where he served in several leadership positions over the course of 5 years and led a multidisciplinary research group in advancing both novel and complex generic products for inflammation, oncology, and cardiovascular disease. Prior to working at Momenta, he served as Senior Director of Inflammation Research at Millennium Pharmaceuticals from 1999 to 2006, where he provided the scientific leadership for 4 programs in clinical development, and as an Associate Director of Research at Boehringer Ingelheim Pharmaceuticals. Dr. Kishimoto has published over 50 peer‑reviewed articles in scientific journals, including Nature, Science, Cell, and The New England Journal of Medicine. Dr. Kishimoto received his B.A. from New College of the University of South Florida and his Ph.D. in Immunology from Harvard University. Prior to joining Selecta Biosciences in 2011, Dr.… Prior to joining Selecta Biosciences in 2011, Dr. Kishimoto was Vice President of Discovery Research at Momenta Pharmaceuticals, where he served in several leadership positions over the course of 5 years and led a multidisciplinary research group in advancing both novel and complex generic products for inflammation, oncology, and cardiovascular disease. Prior to working at Momenta, he served as Senior Director of Inflammation Research at Millennium Pharmaceuticals from 1999 to 2006, where he provided the scientific leadership for 4 programs in clinical development, and as an Associate Director of Research at Boehringer Ingelheim Pharmaceuticals. Dr. Kishimoto has published over 50 peer‑reviewed articles in scientific journals, including Nature, Science, Cell, and The New England Journal of Medicine. Dr. Kishimoto received his B.A. from New College of the University of South Florida and his Ph.D. in Immunology from Harvard University. tag:soundcloud,2010:tracks/820425346 Thu, 14 May 2020 16:52:03 +0000 https://soundcloud.com/trouttalks/melissa-epperly-zentalis-part-of-the-nametag-series 00:20:15 Solebury Trout Talks no Melissa is Chief Financial Officer at Zentalis Pharmaceuticals. She brings extensive experience as a senior financial executive in the life sciences industry. She most recently served as CFO at PsiOxus Therapeutics, a clinical-stage gene therapy cancer company, and prior to that, CFO and Head of Business Development at R-Pharm US, a commercial-stage oncology company. Previously, Melissa was a Director at Anchorage Capital Group, a credit-focused hedge fund; a Vice President at Goldman Sachs in equity research in New York and London where she built GS SUSTAIN; and a management consultant with Bain & Company focused on international and US based pharmaceutical clients and private equity. She began her career at Morgan Stanley in New York in healthcare investment banking. Melissa earned her MBA from Harvard Business School and BA in Biochemistry and Economics from the University of Virginia, where she graduated Phi Beta Kappa. Interesting Fact: Melissa logged six hours towards her pilot’s license and twice attended NASA’s Space Camp before the age of 12. Melissa is Chief Financial Officer at Zentalis Ph… Melissa is Chief Financial Officer at Zentalis Pharmaceuticals. She brings extensive experience as a senior financial executive in the life sciences industry. She most recently served as CFO at PsiOxus Therapeutics, a clinical-stage gene therapy cancer company, and prior to that, CFO and Head of Business Development at R-Pharm US, a commercial-stage oncology company. Previously, Melissa was a Director at Anchorage Capital Group, a credit-focused hedge fund; a Vice President at Goldman Sachs in equity research in New York and London where she built GS SUSTAIN; and a management consultant with Bain & Company focused on international and US based pharmaceutical clients and private equity. She began her career at Morgan Stanley in New York in healthcare investment banking. Melissa earned her MBA from Harvard Business School and BA in Biochemistry and Economics from the University of Virginia, where she graduated Phi Beta Kappa. Interesting Fact: Melissa logged six hours towards her pilot’s license and twice attended NASA’s Space Camp before the age of 12. tag:soundcloud,2010:tracks/814107763 Wed, 06 May 2020 13:16:55 +0000 https://soundcloud.com/trouttalks/richard-godfrey-bergenbio-part-of-the-nametag-series 00:23:41 Solebury Trout Talks no Richard Godfrey joined BerGenBio as Chief Executive Officer in 2008. He has more than 25 years' industry experience leading many international drug development and commercialisation partnerships. Formerly he served as Chief Executive Officer of Aenova Inc., a specialist biopharmaceutical company. Prior to this he was the Managing Director of DCC Healthcare Ltd and previously he held positions of increasing responsibility at Catalant, Eli Lilly and Reckitt Benckiser in RnD and commercial roles. He qualified as a Pharmacist from Liverpool University and received his M.B.A. from Bath University. Richard Godfrey joined BerGenBio as Chief Executi… Richard Godfrey joined BerGenBio as Chief Executive Officer in 2008. He has more than 25 years' industry experience leading many international drug development and commercialisation partnerships. Formerly he served as Chief Executive Officer of Aenova Inc., a specialist biopharmaceutical company. Prior to this he was the Managing Director of DCC Healthcare Ltd and previously he held positions of increasing responsibility at Catalant, Eli Lilly and Reckitt Benckiser in RnD and commercial roles. He qualified as a Pharmacist from Liverpool University and received his M.B.A. from Bath University. tag:soundcloud,2010:tracks/774970042 Mon, 16 Mar 2020 13:04:24 +0000 https://soundcloud.com/trouttalks/gerben-moolhuizen-isa-pharmaceuticals-part-of-the-nametag-series 00:19:21 Solebury Trout Talks no Gerben Moolhuizen has over twenty years of experience in the pharmaceutical and biotechnology industry in various roles covering business development, product development and general management. Prior to ISA Pharmaceuticals, he worked at OctoPlus, where his most recent role was General Manager. He has been closely involved in the company´s fundraising activities, IPO, and the acquisition by Dr. Reddy’s and has also been responsible for the subsequent integration of OctoPlus into Dr. Reddy’s R&D organization. Prior to OctoPlus, Gerben Moolhuizen worked, among others, at Pharming, where he held various roles in business development and product development and was also involved in the company´s IPO in 1998. He holds an M.Sc. from Utrecht University in Medical Biology and an MBA from Erasmus University Rotterdam. Gerben Moolhuizen has over twenty years of experi… Gerben Moolhuizen has over twenty years of experience in the pharmaceutical and biotechnology industry in various roles covering business development, product development and general management. Prior to ISA Pharmaceuticals, he worked at OctoPlus, where his most recent role was General Manager. He has been closely involved in the company´s fundraising activities, IPO, and the acquisition by Dr. Reddy’s and has also been responsible for the subsequent integration of OctoPlus into Dr. Reddy’s R&D organization. Prior to OctoPlus, Gerben Moolhuizen worked, among others, at Pharming, where he held various roles in business development and product development and was also involved in the company´s IPO in 1998. He holds an M.Sc. from Utrecht University in Medical Biology and an MBA from Erasmus University Rotterdam. tag:soundcloud,2010:tracks/756411316 Fri, 07 Feb 2020 15:02:00 +0000 https://soundcloud.com/trouttalks/brian-culley-lineage-cell-therapeutics-part-of-the-nametag-series 00:25:18 Solebury Trout Talks no Mr. Culley joined Lineage as CEO in September 2018. Prior to joining Lineage, Mr. Culley served from August 2017 to September 17, 2018 as Interim Chief Executive Officer at Artemis Therapeutics, Inc., a, where he was responsible for the management of the company. Mr. Culley previously served as Chief Executive Officer of Mast Therapeutics, Inc. (“Mast”), from February 2010, and was also a member of its Board of Directors from December 2011, until Mast’s merger with Savara, Inc. in April 2017. Mr. Culley served from January 2007 to February 2010 as Mast’s Chief Business Officer and Senior Vice President, from February 2006 to January 2007 as Mast’s Senior Vice President, Business Development, and from December 2004 to February 2006 as Mast’s Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. Mr. Culley has more than 25 years of business and scientific experience in the life sciences industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University. Mr. Culley joined Lineage as CEO in September 201… Mr. Culley joined Lineage as CEO in September 2018. Prior to joining Lineage, Mr. Culley served from August 2017 to September 17, 2018 as Interim Chief Executive Officer at Artemis Therapeutics, Inc., a, where he was responsible for the management of the company. Mr. Culley previously served as Chief Executive Officer of Mast Therapeutics, Inc. (“Mast”), from February 2010, and was also a member of its Board of Directors from December 2011, until Mast’s merger with Savara, Inc. in April 2017. Mr. Culley served from January 2007 to February 2010 as Mast’s Chief Business Officer and Senior Vice President, from February 2006 to January 2007 as Mast’s Senior Vice President, Business Development, and from December 2004 to February 2006 as Mast’s Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. Mr. Culley has more than 25 years of business and scientific experience in the life sciences industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University. tag:soundcloud,2010:tracks/695563375 Mon, 14 Oct 2019 16:21:28 +0000 https://soundcloud.com/trouttalks/antonin-de-fougerolles-evox-part-of-the-nametag-series 00:26:16 Solebury Trout Talks no Tony has over 20 years of biotech R&D experience in building out drug pipelines, and he has played a key role in developing and successfully advancing 3 new drug modalities towards the market (RNAi, modified mRNA, single domain antibodies) and in helping build several multi-billion dollar companies from start-up stage. Prior to joining Evox, Tony was CSO of Ablynx, where he led the company’s non-clinical R&D operations, including Discovery, Pharmacology, CMC, and Clinical Trial Drug Supply, and played a key role in the approval of the 1st single domain antibody drug. Prior to Ablynx, Tony was founding CSO at Moderna Therapeutics pioneering modified mRNA as a new therapeutic modality, CSO of antibody-based immuno-oncology company Tolerx Inc, and VP Research at Alnylam where he helped develop RNAi as a new therapeutic modality, including overseeing the development of the now 1st approved RNAi delivery system. Also, Tony has been Principal Investigator on over $80m in grants, has over 60 scientific publications, and is an inventor on over 90 issued U.S. patents. He also serves on the Scientific Advisory Boards of MiNA Therapeutics and LIfT BioSciences. Tony earned his Ph.D. in Immunology from Harvard University. Tony has over 20 years of biotech R&D experience … Tony has over 20 years of biotech R&D experience in building out drug pipelines, and he has played a key role in developing and successfully advancing 3 new drug modalities towards the market (RNAi, modified mRNA, single domain antibodies) and in helping build several multi-billion dollar companies from start-up stage. Prior to joining Evox, Tony was CSO of Ablynx, where he led the company’s non-clinical R&D operations, including Discovery, Pharmacology, CMC, and Clinical Trial Drug Supply, and played a key role in the approval of the 1st single domain antibody drug. Prior to Ablynx, Tony was founding CSO at Moderna Therapeutics pioneering modified mRNA as a new therapeutic modality, CSO of antibody-based immuno-oncology company Tolerx Inc, and VP Research at Alnylam where he helped develop RNAi as a new therapeutic modality, including overseeing the development of the now 1st approved RNAi delivery system. Also, Tony has been Principal Investigator on over $80m in grants, has over 60 scientific publications, and is an inventor on over 90 issued U.S. patents. He also serves on the Scientific Advisory Boards of MiNA Therapeutics and LIfT BioSciences. Tony earned his Ph.D. in Immunology from Harvard University. tag:soundcloud,2010:tracks/684169889 Fri, 20 Sep 2019 18:23:22 +0000 https://soundcloud.com/trouttalks/laura-benjamin-oncologie-part-of-the-nametag-series 00:27:26 Solebury Trout Talks no Laura brings scientific vision and leadership experience from her years as faculty at Harvard Medical School and Vice President at ImClone Systems and Eli Lilly. She has focused her scientific career on cancer biology and clinical biomarker strategies. Laura brings scientific vision and leadership exp… Laura brings scientific vision and leadership experience from her years as faculty at Harvard Medical School and Vice President at ImClone Systems and Eli Lilly. She has focused her scientific career on cancer biology and clinical biomarker strategies. tag:soundcloud,2010:tracks/675914528 Tue, 03 Sep 2019 21:01:51 +0000 https://soundcloud.com/trouttalks/frank-borriello-alloplex-part-of-the-nametag-series 00:27:18 Solebury Trout Talks no A physician-scientist, with a specialization in clinical pathology, oncology, and immunology. A trained immunologist with an academic appointment at the Brigham and Women’s Hospital (BWH) prior to 18 years experience in the pharmaceutical industry. A physician-scientist, with a specialization in c… A physician-scientist, with a specialization in clinical pathology, oncology, and immunology. A trained immunologist with an academic appointment at the Brigham and Women’s Hospital (BWH) prior to 18 years experience in the pharmaceutical industry. tag:soundcloud,2010:tracks/663556964 Fri, 09 Aug 2019 18:19:27 +0000 https://soundcloud.com/trouttalks/adi-hoess-affimed-part-of-the-nametag-series 00:27:28 Solebury Trout Talks no Dr. Hoess joined Affimed in October 2010 as Chief Commercial Officer and since September 2011 has led the company as CEO. He has more than 20 years of professional experience with an extensive background in general management, business development, product commercialization, fund raising and M&A. Dr. Hoess joined Affimed in October 2010 as Chief… Dr. Hoess joined Affimed in October 2010 as Chief Commercial Officer and since September 2011 has led the company as CEO. He has more than 20 years of professional experience with an extensive background in general management, business development, product commercialization, fund raising and M&A. tag:soundcloud,2010:tracks/662587052 Wed, 07 Aug 2019 19:19:21 +0000 https://soundcloud.com/trouttalks/ralph-kern-brainstorm-part-of-the-nametag-series 00:24:51 Solebury Trout Talks no Ralph Kern, MD, MHSc, is Chief Operating Officer and Chief Medical Officer at BrainStorm. He brings significant industry and neurodegenerative disease experience to the organization. His biotech experience includes senior medical roles at Genzyme, Novartis, and Biogen. At Novartis he was Vice President and Head of the Neuroscience Medical Team, leading the global launch of Gilenya® in relapsing remitting multiple sclerosis (rrMS). At Biogen he was Senior Vice President and Head of the Worldwide Medical Organization. His team launched Zinbryta® in rrMS and Spinraza® in spinal muscular atrophy (SMA), and developed the medical and scientific strategy for MS, SMA, and Alzheimer’s disease. Ralph Kern, MD, MHSc, is Chief Operating Officer … Ralph Kern, MD, MHSc, is Chief Operating Officer and Chief Medical Officer at BrainStorm. He brings significant industry and neurodegenerative disease experience to the organization. His biotech experience includes senior medical roles at Genzyme, Novartis, and Biogen. At Novartis he was Vice President and Head of the Neuroscience Medical Team, leading the global launch of Gilenya® in relapsing remitting multiple sclerosis (rrMS). At Biogen he was Senior Vice President and Head of the Worldwide Medical Organization. His team launched Zinbryta® in rrMS and Spinraza® in spinal muscular atrophy (SMA), and developed the medical and scientific strategy for MS, SMA, and Alzheimer’s disease. tag:soundcloud,2010:tracks/656810147 Fri, 26 Jul 2019 16:00:15 +0000 https://soundcloud.com/trouttalks/david-hilbert-arcellx-part-of-the-nametag-series 00:20:05 Solebury Trout Talks no David Hilbert has spent the past 20+ years combining his disciplined approach to science with the business of effective drug development and corporate management. He is currently President and CEO at Arcellx, Inc., a company focused on the development of regulated immune cell therapies for treatment of human disease. From 2009-2014, David was the CSO at Zyngenia, Inc., and led the company’s development of multi-specific antibody-based therapeutics. From 2006 to 2009, David consulted with leading scientists, executives, and venture firms in assisting startup biotech companies with the many strategic and operational challenges associated with early stage drug development. In 2004, he served as Vice President of Research at Cellective Therapeutics, a start-up antibody company acquired by MedImmune in October 2005. David began his biotech career in 1996 at Human Genome Sciences (HGS) where he spent 8 years guiding the preclinical development of antibodies and genomics-based therapeutics. David Hilbert has spent the past 20+ years combin… David Hilbert has spent the past 20+ years combining his disciplined approach to science with the business of effective drug development and corporate management. He is currently President and CEO at Arcellx, Inc., a company focused on the development of regulated immune cell therapies for treatment of human disease. From 2009-2014, David was the CSO at Zyngenia, Inc., and led the company’s development of multi-specific antibody-based therapeutics. From 2006 to 2009, David consulted with leading scientists, executives, and venture firms in assisting startup biotech companies with the many strategic and operational challenges associated with early stage drug development. In 2004, he served as Vice President of Research at Cellective Therapeutics, a start-up antibody company acquired by MedImmune in October 2005. David began his biotech career in 1996 at Human Genome Sciences (HGS) where he spent 8 years guiding the preclinical development of antibodies and genomics-based therapeutics. tag:soundcloud,2010:tracks/656273690 Thu, 25 Jul 2019 16:58:17 +0000 https://soundcloud.com/trouttalks/dean-hum-genfit-part-of-the-nametag-series 00:27:10 Solebury Trout Talks no Dean Hum earned a Ph.D. in Biochemistry from McGill University in Montreal in 1990. An expert in the modulation of transcription factors and nuclear receptors associated with endocrine and cardiometabolic diseases, he held a research position at the University of California in San Francisco before becoming a Professor at Laval University in Quebec. He joined GENFIT in 2000 as Chief Scientific Officer. Dean Hum is today a key person in the organization of GENFIT. In particular, he is responsible for defining, implementing, employing and coordinating short-, medium- and long-term strategies relating to R&D programs and portfolio. He coordinates all R&D activities with the CEO and in close collaboration with scientific officers and project managers. Dean Hum earned a Ph.D. in Biochemistry from McGi… Dean Hum earned a Ph.D. in Biochemistry from McGill University in Montreal in 1990. An expert in the modulation of transcription factors and nuclear receptors associated with endocrine and cardiometabolic diseases, he held a research position at the University of California in San Francisco before becoming a Professor at Laval University in Quebec. He joined GENFIT in 2000 as Chief Scientific Officer. Dean Hum is today a key person in the organization of GENFIT. In particular, he is responsible for defining, implementing, employing and coordinating short-, medium- and long-term strategies relating to R&D programs and portfolio. He coordinates all R&D activities with the CEO and in close collaboration with scientific officers and project managers. tag:soundcloud,2010:tracks/655777517 Wed, 24 Jul 2019 16:28:11 +0000 https://soundcloud.com/trouttalks/david-shao-yisheng-biopharma-part-of-the-nametag-series 00:21:41 Solebury Trout Talks no Dr. Shao has over 20 years of experience in the biopharmaceutical industry with executive roles in finance, management and business strategy. After eight years as Chief Financial Officer and Global Head of Business, Dr. Shao accepted the role of the President & CEO of Yisheng Biopharma in 2018. Prior to joining Yisheng, Dr. Shao was a principal scientist at Roche conducting drug discovery and technology research. He then became a biotech analyst at Mehta Partners and Kamunting Street Capital. Dr. Shao was Chief Financial Officer of Aoxing Pharmaceutical. Dr. Shao received his Ph.D. in Biochemistry from the University of California San Diego, received his bachelor’s degree from the University of Science and Technology of China and holds an MBA from the Stern School of Business of New York University. Dr. Shao is a certified public accountant (CPA) and is a chartered financial analyst (CFA). Dr. Shao has over 20 years of experience in the b… Dr. Shao has over 20 years of experience in the biopharmaceutical industry with executive roles in finance, management and business strategy. After eight years as Chief Financial Officer and Global Head of Business, Dr. Shao accepted the role of the President & CEO of Yisheng Biopharma in 2018. Prior to joining Yisheng, Dr. Shao was a principal scientist at Roche conducting drug discovery and technology research. He then became a biotech analyst at Mehta Partners and Kamunting Street Capital. Dr. Shao was Chief Financial Officer of Aoxing Pharmaceutical. Dr. Shao received his Ph.D. in Biochemistry from the University of California San Diego, received his bachelor’s degree from the University of Science and Technology of China and holds an MBA from the Stern School of Business of New York University. Dr. Shao is a certified public accountant (CPA) and is a chartered financial analyst (CFA). tag:soundcloud,2010:tracks/653523467 Fri, 19 Jul 2019 15:56:11 +0000 https://soundcloud.com/trouttalks/maria-fardis-iovance-part-of-the-nametag-series 00:17:19 Solebury Trout Talks no Dr. Fardis has extensive experience in drug development and novel cancer treatments. While at Iovance, the lifileucel (TIL for melanoma) has been transformed to a product which is in late stage development toward commercialization for metastatic melanoma. Prior to joining Iovance Biotherapeutics, Dr. Fardis was chief operating officer at Acerta Pharma working on the development of CALQUENCE® (acalabrutinib), until the company’s acquisition by AstraZeneca. Before joining Acerta, Dr. Fardis held the position of chief of oncology operations and alliances at Pharmacyclics where she oversaw development of IMBRUVICA® (ibrutinib). She was a key contributor in the creation of a broad clinical program for ibrutinib, as well as NDA and MAA submissions. Previously, Dr. Fardis held a number of key scientific and management roles at Gilead Sciences. At Gilead, she was involved with multiple therapeutic areas including antivirals, oncology, and cardiovascular therapeutics and worked on the development and life cycle management of LETAIRIS® (ambrisentan). She received her PhD in organic chemistry from UC Berkeley and holds an MBA. Dr. Fardis has extensive experience in drug devel… Dr. Fardis has extensive experience in drug development and novel cancer treatments. While at Iovance, the lifileucel (TIL for melanoma) has been transformed to a product which is in late stage development toward commercialization for metastatic melanoma. Prior to joining Iovance Biotherapeutics, Dr. Fardis was chief operating officer at Acerta Pharma working on the development of CALQUENCE® (acalabrutinib), until the company’s acquisition by AstraZeneca. Before joining Acerta, Dr. Fardis held the position of chief of oncology operations and alliances at Pharmacyclics where she oversaw development of IMBRUVICA® (ibrutinib). She was a key contributor in the creation of a broad clinical program for ibrutinib, as well as NDA and MAA submissions. Previously, Dr. Fardis held a number of key scientific and management roles at Gilead Sciences. At Gilead, she was involved with multiple therapeutic areas including antivirals, oncology, and cardiovascular therapeutics and worked on the development and life cycle management of LETAIRIS® (ambrisentan). She received her PhD in organic chemistry from UC Berkeley and holds an MBA. tag:soundcloud,2010:tracks/652498430 Wed, 17 Jul 2019 15:50:13 +0000 https://soundcloud.com/trouttalks/nametag-with-wolfgang-soehgen-paion-ag 00:20:30 Solebury Trout Talks no Wolfgang Söhngen is founder and CEO of PAION AG and Managing Director of PAION Deutschland GmbH. With his wife Mariola, he has raised more than EUR 170 million through fund raising and EUR 78 million through partnering. Wolfgang has many years of experience in the pharmaceutical industry. He worked for ten years in clinical development, project management, corporate development, and strategic planning at Grünenthal GmbH. Before founding PAION in 2000 with his wife, Mariola, he was head of his own consulting firm, Virtueality, which specialized in healthcare and clinical development. In 1985, Wolfgang received his doctoral degree in medicine from RWTH Aachen (Technical University of Aachen). He worked on the Inner Department of an academic teaching hospital and was then offered a post-doc position in cardiovascular pharmacology at the University of Michigan, Ann Arbor (USA). He also holds a Master of Business Communication and a Diploma in Pharmaceutical Medicine (DGPharMed). Wolfgang Söhngen is founder and CEO of PAION AG a… Wolfgang Söhngen is founder and CEO of PAION AG and Managing Director of PAION Deutschland GmbH. With his wife Mariola, he has raised more than EUR 170 million through fund raising and EUR 78 million through partnering. Wolfgang has many years of experience in the pharmaceutical industry. He worked for ten years in clinical development, project management, corporate development, and strategic planning at Grünenthal GmbH. Before founding PAION in 2000 with his wife, Mariola, he was head of his own consulting firm, Virtueality, which specialized in healthcare and clinical development. In 1985, Wolfgang received his doctoral degree in medicine from RWTH Aachen (Technical University of Aachen). He worked on the Inner Department of an academic teaching hospital and was then offered a post-doc position in cardiovascular pharmacology at the University of Michigan, Ann Arbor (USA). He also holds a Master of Business Communication and a Diploma in Pharmaceutical Medicine (DGPharMed). tag:soundcloud,2010:tracks/521759814 Fri, 02 Nov 2018 14:49:18 +0000 https://soundcloud.com/trouttalks/aurigene-solebury-trout-private-company-showcase-2018 00:15:25 Solebury Trout Talks no Aurigene - Solebury Trout Private Company Showcase 2018 by Solebury Trout Talks Aurigene - Solebury Trout Private Company Showcas… Aurigene - Solebury Trout Private Company Showcase 2018 by Solebury Trout Talks tag:soundcloud,2010:tracks/521801886 Wed, 31 Oct 2018 17:45:19 +0000 https://soundcloud.com/trouttalks/meditope-solebury-trout-private-company-showcase-2018 00:14:24 Solebury Trout Talks no Meditope - Solebury Trout Private Company Showcase 2018 by Solebury Trout Talks Meditope - Solebury Trout Private Company Showcas… Meditope - Solebury Trout Private Company Showcase 2018 by Solebury Trout Talks tag:soundcloud,2010:tracks/521803704 Wed, 31 Oct 2018 16:40:25 +0000 https://soundcloud.com/trouttalks/rani-solebury-trout-private-company-showcase-2018 00:10:53 Solebury Trout Talks no Rani - Solebury Trout Private Company Showcase 2018 by Solebury Trout Talks Rani - Solebury Trout Private Company Showcase 20… Rani - Solebury Trout Private Company Showcase 2018 by Solebury Trout Talks tag:soundcloud,2010:tracks/521758434 Wed, 31 Oct 2018 16:39:50 +0000 https://soundcloud.com/trouttalks/alphacancer-solebury-trout-private-company-showcase-2018 00:18:01 Solebury Trout Talks no AlphaCancer - Solebury Trout Private Company Showcase 2018 by Solebury Trout Talks AlphaCancer - Solebury Trout Private Company Show… AlphaCancer - Solebury Trout Private Company Showcase 2018 by Solebury Trout Talks tag:soundcloud,2010:tracks/521800317 Wed, 31 Oct 2018 15:29:40 +0000 https://soundcloud.com/trouttalks/engage-solebury-trout-private-company-showcase-2018 00:15:27 Solebury Trout Talks no Engage - Solebury Trout Private Company Showcase 2018 by Solebury Trout Talks Engage - Solebury Trout Private Company Showcase … Engage - Solebury Trout Private Company Showcase 2018 by Solebury Trout Talks tag:soundcloud,2010:tracks/521803002 Tue, 30 Oct 2018 21:18:28 +0000 https://soundcloud.com/trouttalks/nuview-solebury-trout-private-company-showcase-2018 00:15:12 Solebury Trout Talks no NuView - Solebury Trout Private Company Showcase 2018 by Solebury Trout Talks NuView - Solebury Trout Private Company Showcase … NuView - Solebury Trout Private Company Showcase 2018 by Solebury Trout Talks tag:soundcloud,2010:tracks/521756463 Tue, 30 Oct 2018 20:54:28 +0000 https://soundcloud.com/trouttalks/agrimetis-solebury-trout-private-company-showcase-2018 00:12:43 Solebury Trout Talks no To utilize innovative, leading edge methods of Discovery, Development, and Delivery to provide the global community with sustainable crop protection products. To utilize innovative, leading edge methods of Di… To utilize innovative, leading edge methods of Discovery, Development, and Delivery to provide the global community with sustainable crop protection products. tag:soundcloud,2010:tracks/521803365 Tue, 30 Oct 2018 20:45:26 +0000 https://soundcloud.com/trouttalks/pliant-solebury-trout-private-company-showcase-2018 00:14:27 Solebury Trout Talks no Pliant - Solebury Trout Private Company Showcase 2018 by Solebury Trout Talks Pliant - Solebury Trout Private Company Showcase … Pliant - Solebury Trout Private Company Showcase 2018 by Solebury Trout Talks tag:soundcloud,2010:tracks/521801412 Tue, 30 Oct 2018 20:44:04 +0000 https://soundcloud.com/trouttalks/flx-solebury-trout-private-company-showcase-2018 00:16:13 Solebury Trout Talks no FLX - Solebury Trout Private Company Showcase 2018 by Solebury Trout Talks FLX - Solebury Trout Private Company Showcase 201… FLX - Solebury Trout Private Company Showcase 2018 by Solebury Trout Talks tag:soundcloud,2010:tracks/398416314 Mon, 12 Feb 2018 14:43:58 +0000 https://soundcloud.com/trouttalks/trouttalks-ep17-gary-anderson-anticalins 00:24:54 Solebury Trout Talks no Gary Anderson is a pharmacologist and immunologist based in the Medical Faculty at the University of Melbourne, Australia, one of the world’s leading research-intensive Universities and Medical Schools (www.unimelb.edu.au) where he is a tenured Professor and Director of the Centre for Lung Health Research. Gary Anderson is a pharmacologist and immunologis… Gary Anderson is a pharmacologist and immunologist based in the Medical Faculty at the University of Melbourne, Australia, one of the world’s leading research-intensive Universities and Medical Schools (www.unimelb.edu.au) where he is a tenured Professor and Director of the Centre for Lung Health Research. tag:soundcloud,2010:tracks/322767408 Mon, 15 May 2017 19:07:42 +0000 https://soundcloud.com/trouttalks/trouttalks-ep16-dr-sameer-bansilal-pcsk9-inhibitors 01:04:11 Solebury Trout Talks no American Heart Association and The Trout Group co-hosted a TroutTalk by Sameer Bansilal, MD, MS, Assistant Professor of Medicine, Cardiology at The Mount Sinai Hospital. American Heart Association and The Trout Group co… American Heart Association and The Trout Group co-hosted a TroutTalk by Sameer Bansilal, MD, MS, Assistant Professor of Medicine, Cardiology at The Mount Sinai Hospital. tag:soundcloud,2010:tracks/310559713 Fri, 03 Mar 2017 19:09:04 +0000 https://soundcloud.com/trouttalks/ep_14 01:16:50 Solebury Trout Talks no Dr. Phil Greenberg from the Fred Hutchinson Cancer Research Center, talked about “Engineering T Cells to be Effective in Tumor Therapy” Dr. Phil Greenberg from the Fred Hutchinson Canc… Dr. Phil Greenberg from the Fred Hutchinson Cancer Research Center, talked about “Engineering T Cells to be Effective in Tumor Therapy” tag:soundcloud,2010:tracks/289342918 Fri, 21 Oct 2016 00:00:00 +0000 https://soundcloud.com/trouttalks/trouttalks-ep12-dr-peter-hotez-zika-pandemic 00:24:23 Solebury Trout Talks no In an ever more global world, pandemics are an increasing threat. Dr. Peter Hotez, President of the Sabin Vaccine Institute and Dean of the National School of Tropical Medicine and Professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine, will discuss Zika, the rise of vector borne diseases and the development of vaccines. In an ever more global world, pandemics are an in… In an ever more global world, pandemics are an increasing threat. Dr. Peter Hotez, President of the Sabin Vaccine Institute and Dean of the National School of Tropical Medicine and Professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine, will discuss Zika, the rise of vector borne diseases and the development of vaccines. tag:soundcloud,2010:tracks/285423295 Fri, 30 Sep 2016 14:04:39 +0000 https://soundcloud.com/trouttalks/trouttalks-ep11-louis-matis-cmo-of-pieries-talks-about-his-past-career-advantages-of-anticalins 00:40:08 Solebury Trout Talks no Dr. Louis Matis joined Pieris as the Senior Vice President and Chief Development Officer in August 2015, bringing more than 30 years of experience in basic and clinical biomedical research, regulatory affairs, drug development and executive leadership. Prior to joining Pieris, Dr. Matis served since June 2011 as Executive Director, Strategic Evaluation at Alexion Pharmaceuticals, where he also served from 1993 to 2000, during which time he advanced to the position of CSO and had a leading role in discovering the first-in-class complement inhibitor monoclonal antibody Soliris® (eculizumab). Before re-joining Alexion in 2011, Dr. Matis served as CEO of CGI Pharmaceuticals, Inc. from 2000 to 2006, and of the Immune Tolerance Institute from 2007 to 2010. Under Dr. Matis’ leadership, CGI raised over $60 million in venture capital financing, established five partnerships with top tier pharmaceutical and biotechnology companies, and developed novel small molecule kinase inhibitors for both autoimmune disease and cancer indications. From 1977 until joining Alexion in 1993, Dr. Matis held senior research and clinical positions at the National Cancer Institute, National Institutes of Health, and the FDA Center for Biologics Evaluation and Research. Dr. Matis holds a B.A. from Amherst College and an M.D. from the University of Pennsylvania, Perelman School of Medicine. He completed his clinical training in Internal Medicine at the University of Chicago Hospitals and Clinics, and in Medical Oncology at the NCI. Dr. Matis is the author of over 120 publications in the fields of immunology, cell and molecular biology, and clinical medicine. Dr. Louis Matis joined Pieris as the Senior Vice … Dr. Louis Matis joined Pieris as the Senior Vice President and Chief Development Officer in August 2015, bringing more than 30 years of experience in basic and clinical biomedical research, regulatory affairs, drug development and executive leadership. Prior to joining Pieris, Dr. Matis served since June 2011 as Executive Director, Strategic Evaluation at Alexion Pharmaceuticals, where he also served from 1993 to 2000, during which time he advanced to the position of CSO and had a leading role in discovering the first-in-class complement inhibitor monoclonal antibody Soliris® (eculizumab). Before re-joining Alexion in 2011, Dr. Matis served as CEO of CGI Pharmaceuticals, Inc. from 2000 to 2006, and of the Immune Tolerance Institute from 2007 to 2010. Under Dr. Matis’ leadership, CGI raised over $60 million in venture capital financing, established five partnerships with top tier pharmaceutical and biotechnology companies, and developed novel small molecule kinase inhibitors for both autoimmune disease and cancer indications. From 1977 until joining Alexion in 1993, Dr. Matis held senior research and clinical positions at the National Cancer Institute, National Institutes of Health, and the FDA Center for Biologics Evaluation and Research. Dr. Matis holds a B.A. from Amherst College and an M.D. from the University of Pennsylvania, Perelman School of Medicine. He completed his clinical training in Internal Medicine at the University of Chicago Hospitals and Clinics, and in Medical Oncology at the NCI. Dr. Matis is the author of over 120 publications in the fields of immunology, cell and molecular biology, and clinical medicine. tag:soundcloud,2010:tracks/271449767 Wed, 29 Jun 2016 20:07:18 +0000 https://soundcloud.com/trouttalks/trouttalks-ep10-dr-chrystal-mackall-immunotherapy-a-new-paradigm-in-cancer-treatment 01:11:05 Solebury Trout Talks no Dr. Crystal L. Mackall, MD, serves as a Professor of Pediatrics and of Medicine at Stanford University School of Medicine. Dr. Mackall co-leads the StandUp2Cancer/St.Baldrick’s/NCI Pediatric Dream Team. An expert in the field of T-cell homeostasis, Dr. Mackall has experience leading clinical trials of engineered T-cell and Natural Killer cell therapies. Her work focuses on translational research and immunotherapy for childhood cancers. She has been Member of Scientific Advisory Board at Unum Therapeutics, Inc. since February 2, 2016. She serves as Associate Director of the Stanford Cancer Institute, Co-Medical Director of the Stanford Laboratory for Cell and Gene Medicine, and as Program Leader in pediatric cancer immunotherapy. She served as Head of Immunology Section and Chief of the Pediatric Oncology Branch at National Cancer Institute having spent much of her career. Dr. Crystal L. Mackall, MD, serves as a Professor… Dr. Crystal L. Mackall, MD, serves as a Professor of Pediatrics and of Medicine at Stanford University School of Medicine. Dr. Mackall co-leads the StandUp2Cancer/St.Baldrick’s/NCI Pediatric Dream Team. An expert in the field of T-cell homeostasis, Dr. Mackall has experience leading clinical trials of engineered T-cell and Natural Killer cell therapies. Her work focuses on translational research and immunotherapy for childhood cancers. She has been Member of Scientific Advisory Board at Unum Therapeutics, Inc. since February 2, 2016. She serves as Associate Director of the Stanford Cancer Institute, Co-Medical Director of the Stanford Laboratory for Cell and Gene Medicine, and as Program Leader in pediatric cancer immunotherapy. She served as Head of Immunology Section and Chief of the Pediatric Oncology Branch at National Cancer Institute having spent much of her career. tag:soundcloud,2010:tracks/269629685 Fri, 17 Jun 2016 18:30:14 +0000 https://soundcloud.com/trouttalks/trouttalks-ep-9-dr-john-bell-oncolytic-viruses-biological-machines-for-cancer-therapy 00:55:26 Solebury Trout Talks no Dr. John Bell received his PhD from McMaster University in 1982. The three years that followed, he trained as a post-doctoral fellow at the University of Ottawa and then at the Medical Research Council in London, England. Dr. Bell began his independent research career at McGill University in 1986 and moved to the University of Ottawa, Department of Medicine, in 1989. He is a member of the Center for Cancer Therapeutics at The Ottawa Hospital Cancer Center, a Senior Scientist with the Ottawa Hospital Research Institute and Professor of Medicine at the University of Ottawa. He heads the Canadian Oncolytic Virus Consortium, a Terry Fox funded group from across Canada that is developing virus based cancer therapeutics and is the Director of the Biotherapeutics Program for the Ontario Institute for Cancer Research. He is the Scientific Director of the National Centre of Excellence for the development of Biotherapeutics for Cancer Therapy and is a fellow of the Royal Society of Canada. Dr. John Bell received his PhD from McMaster Univ… Dr. John Bell received his PhD from McMaster University in 1982. The three years that followed, he trained as a post-doctoral fellow at the University of Ottawa and then at the Medical Research Council in London, England. Dr. Bell began his independent research career at McGill University in 1986 and moved to the University of Ottawa, Department of Medicine, in 1989. He is a member of the Center for Cancer Therapeutics at The Ottawa Hospital Cancer Center, a Senior Scientist with the Ottawa Hospital Research Institute and Professor of Medicine at the University of Ottawa. He heads the Canadian Oncolytic Virus Consortium, a Terry Fox funded group from across Canada that is developing virus based cancer therapeutics and is the Director of the Biotherapeutics Program for the Ontario Institute for Cancer Research. He is the Scientific Director of the National Centre of Excellence for the development of Biotherapeutics for Cancer Therapy and is a fellow of the Royal Society of Canada. tag:soundcloud,2010:tracks/269404733 Thu, 16 Jun 2016 14:37:18 +0000 https://soundcloud.com/trouttalks/trouttalks-ep8-dr-eric-pierce-treatment-of-retinitis-pigmentosa 00:19:17 Solebury Trout Talks no Dr. Pierce is an ophthalmologist and molecular geneticist whose research program is dedicated to understanding the molecular mechanisms of Inherited retinal degenerations (IRDs) and improving therapeutic interventions for these conditions. IRDs are a leading cause of blindness worldwide, and are characterized by progressive dysfunctionand death of retinal photoreceptor cells. Dr. Pierce's research program is focused on identifying new IRD disease genes, investigating the mechanism by which mutations in the identified genes lead to blindness, and using this information about disease pathogenesis to develop gene and genetic therapies to prevent vision loss. Dr. Pierce is an ophthalmologist and molecular ge… Dr. Pierce is an ophthalmologist and molecular geneticist whose research program is dedicated to understanding the molecular mechanisms of Inherited retinal degenerations (IRDs) and improving therapeutic interventions for these conditions. IRDs are a leading cause of blindness worldwide, and are characterized by progressive dysfunctionand death of retinal photoreceptor cells. Dr. Pierce's research program is focused on identifying new IRD disease genes, investigating the mechanism by which mutations in the identified genes lead to blindness, and using this information about disease pathogenesis to develop gene and genetic therapies to prevent vision loss. tag:soundcloud,2010:tracks/269278310 Wed, 15 Jun 2016 20:54:04 +0000 https://soundcloud.com/trouttalks/trouttalks-ep7-dr-michael-young-human-retinal-progenitor-cell-therapy 00:17:09 Solebury Trout Talks no Dr. Young studies the repair of the mature, diseased central nervous system, specifically the degeneration that occurs in the retina during disease or injury. He is currently studying human retinal stem cells with the goal of transplanting these cells to the diseased eye to establish functional connectivity between donor retinal stem cells and the mature, diseased host retina. Studies include gene and protein expression, substrate specific differentiation, and retinal transplantation in mice and pigs. Dr. Young studies the repair of the mature, disea… Dr. Young studies the repair of the mature, diseased central nervous system, specifically the degeneration that occurs in the retina during disease or injury. He is currently studying human retinal stem cells with the goal of transplanting these cells to the diseased eye to establish functional connectivity between donor retinal stem cells and the mature, diseased host retina. Studies include gene and protein expression, substrate specific differentiation, and retinal transplantation in mice and pigs. tag:soundcloud,2010:tracks/257671912 Wed, 06 Apr 2016 20:16:05 +0000 https://soundcloud.com/trouttalks/trouttalks-ep6-dr-charles-g-drake-aacr-preview-bispecifics-and-check-points 00:38:35 Solebury Trout Talks no Dr. Charles G. Drake is an Associate Professor of Oncology, Urology, and Immunology at Johns Hopkins School of Medicine. Dr. Drake’s expertise is in the use of checkpoint inhibitors, the immunotherapy agents that have made such an impact in the treatment of certain solid tumors. His work has also recently been focused on the use of radiation in conjunction with checkpoint blockade. Dr. Charles G. Drake is an Associate Professor of… Dr. Charles G. Drake is an Associate Professor of Oncology, Urology, and Immunology at Johns Hopkins School of Medicine. Dr. Drake’s expertise is in the use of checkpoint inhibitors, the immunotherapy agents that have made such an impact in the treatment of certain solid tumors. His work has also recently been focused on the use of radiation in conjunction with checkpoint blockade. tag:soundcloud,2010:tracks/257670647 Wed, 06 Apr 2016 20:07:45 +0000 https://soundcloud.com/trouttalks/trouttalks-ep5-dr-marcela-v-maus-aacr-preview 00:46:35 Solebury Trout Talks no Dr. Marcela V. Maus is the Director of Cellular Immunotherapy at the MGH Cancer Center and a Member of the Faculty at Harvard Medical School. Dr. Maus has performed extensive investigations in the biology of T cell receptors, including the design and manufacture of chimeric antigen receptors – so called CARs – a technology that has already revolutionized the treatment of certain blood cancers. Dr. Marcela V. Maus is the Director of Cellular I… Dr. Marcela V. Maus is the Director of Cellular Immunotherapy at the MGH Cancer Center and a Member of the Faculty at Harvard Medical School. Dr. Maus has performed extensive investigations in the biology of T cell receptors, including the design and manufacture of chimeric antigen receptors – so called CARs – a technology that has already revolutionized the treatment of certain blood cancers. tag:soundcloud,2010:tracks/256324755 Wed, 30 Mar 2016 20:07:33 +0000 https://soundcloud.com/trouttalks/trouttalks-ep4 01:08:38 Solebury Trout Talks no Leisha Emens is an Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center where she and specializes in cancer immunotherapy. Her research focuses on the development and implementation of breast cancer immunotherapies (including vaccination strategies and immune checkpoint blockade) in combination with traditional anticancer therapies and newer biologically targeted therapies. She is a member of the FDA Advisory Committee on Cell, Tissue, and Gene Therapies, and on the editorial boards of the Journal of Clinical Oncology, Cancer Research, and the Journal for the Immunotherapy of Cancer. Amongst other topics, Dr. Emens will discuss her work with breast GVAX, a vaccine that has already demonstrated safety and immune activity in in early trials. This year Dr. Emens, and co-investigator, Dr. Elizabeth Jaffee will combine GVAX with a newly developed immune adjuvant called STING to enhance immunity. Leisha Emens is an Associate Professor of Oncolog… Leisha Emens is an Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center where she and specializes in cancer immunotherapy. Her research focuses on the development and implementation of breast cancer immunotherapies (including vaccination strategies and immune checkpoint blockade) in combination with traditional anticancer therapies and newer biologically targeted therapies. She is a member of the FDA Advisory Committee on Cell, Tissue, and Gene Therapies, and on the editorial boards of the Journal of Clinical Oncology, Cancer Research, and the Journal for the Immunotherapy of Cancer. Amongst other topics, Dr. Emens will discuss her work with breast GVAX, a vaccine that has already demonstrated safety and immune activity in in early trials. This year Dr. Emens, and co-investigator, Dr. Elizabeth Jaffee will combine GVAX with a newly developed immune adjuvant called STING to enhance immunity. tag:soundcloud,2010:tracks/249058420 Fri, 26 Feb 2016 19:49:17 +0000 https://soundcloud.com/trouttalks/trouttalks-ep3 01:18:38 Solebury Trout Talks no Dr. Louis Weiner, Director of the Lombardi Cancer Center, Board member of the Antibody Society, and co-founder of Jounce Therapeutics is an internationally recognized medical oncologist specializing in the treatment in gastrointestinal cancers. Additionally, Dr. Weiner is an accomplished researcher developing novel immunotherapy treatments for cancer, widely known for his work in antibody-based therapeutics, including the development of bi-specific antibodies. Dr. Louis Weiner, Director of the Lombardi Cancer… Dr. Louis Weiner, Director of the Lombardi Cancer Center, Board member of the Antibody Society, and co-founder of Jounce Therapeutics is an internationally recognized medical oncologist specializing in the treatment in gastrointestinal cancers. Additionally, Dr. Weiner is an accomplished researcher developing novel immunotherapy treatments for cancer, widely known for his work in antibody-based therapeutics, including the development of bi-specific antibodies. tag:soundcloud,2010:tracks/249057337 Fri, 26 Feb 2016 19:42:10 +0000 https://soundcloud.com/trouttalks/trouttalks-ep2 01:10:14 Solebury Trout Talks no Dr. Dario Vignali PhD, Vice Chair and Professor of Immunology, University of Pittsburgh School of Medicine who will present “Targeting T-Regs” with a focus on LAG-3 in New York City. Dr. Dario Vignali PhD, Vice Chair and Professor o… Dr. Dario Vignali PhD, Vice Chair and Professor of Immunology, University of Pittsburgh School of Medicine who will present “Targeting T-Regs” with a focus on LAG-3 in New York City. tag:soundcloud,2010:tracks/249052179 Fri, 26 Feb 2016 19:07:54 +0000 https://soundcloud.com/trouttalks/trouttalks-ep-1 01:05:34 Solebury Trout Talks no Dr. Christopher Heery, MD, Director of the Clinical Trials Group of Tumor Immunology and Biology at the National Cancer Institute, and an expert in the field of cancer vaccines. Dr. Christopher Heery, MD, Director of the Clinic… Dr. Christopher Heery, MD, Director of the Clinical Trials Group of Tumor Immunology and Biology at the National Cancer Institute, and an expert in the field of cancer vaccines.